In the second quarter of 2026, Johnson & Johnson reported $25.310 billion in sales, while Bristol Myers Squibb reported $12.973 billion in total revenues. The figures are company-reported top-line measures for the quarter ended June 30, 2026; their labels and underlying composition are not identical.
Q2 2026 reported top-line comparison
| Company | Q2 2026 amount | Company’s measure label | Q2 2025 amount | Year-over-year reported growth |
|---|---|---|---|---|
| Bristol Myers Squibb (NYSE: BMY) | $12.973 billion | Total revenues | $12.269 billion | 6% |
| Johnson & Johnson (NYSE: JNJ) | $25.310 billion | Reported sales | $23.743 billion | 6.6% |
BMS’s figures are from its Form 10-Q for the quarter ended June 30, 2026 and Q2 earnings release dated July 30, 2026. J&J’s figures are from its Q2 results release published July 15, 2026.
What the bar comparison does—and does not—show
On a common U.S.-dollar scale, J&J’s reported Q2 amount was just under twice BMS’s: $25.310 billion versus $12.973 billion. That is a comparison of reported top-line scale for the same quarter, not a claim that the companies’ accounting measures have identical composition. BMS calls its amount “total revenues” and reports net product sales alongside alliance and other revenues. J&J calls its amount “reported sales” and breaks sales out between Innovative Medicine and MedTech.
For a two-bar graphic, use one zero-based axis in U.S. dollars (billions), label each bar with its amount, and identify the period as Q2 2026. The issuer labels—“Total revenues” for BMS and “Reported sales” for J&J—belong in the chart labels or caption. The Q2 2025 amounts and growth rates are useful context, but they should be presented as comparisons, not as additional revenue bars on a chart of Q2 2026.
#1 Best Overall
Reported growth is not the same as currency-adjusted growth
The growth rates in the table compare each company’s reported Q2 2026 amount with its reported Q2 2025 amount. BMS also reported 5% growth excluding foreign exchange, compared with 6% reported growth. J&J reported 5.6% operational growth excluding translational currency and 5.7% adjusted operational growth excluding the net impact of acquisitions and divestitures and translational currency. Those are separate measures with different adjustments; they should not be substituted for reported growth or shown as revenue amounts. The definitions and results appear in the companies’ respective BMS release and J&J release.
Independent reader supportYour contribution helps us test, update, and keep practical guides available for everyone.How to read the period and source figures
Both comparisons are for Q2 2026, so they align by quarter. BMS’s Form 10-Q states its interim financial statements are unaudited and presents amounts in millions; it notes amounts may not sum because of rounding. The reported values above are converted to billions for readability. J&J’s July 15 release provides its Q2 reported sales and prior-year comparison. These are interim company-reported results, not full-year totals.
Rank #2
- Ideal for Gifting
- Ideal for a bookworm
- Compact for travelling
The figures are a dated snapshot: as of October 3, 2026, they represent the latest quarterly amounts in this comparison. For subsequent quarters, check the companies’ filings and earnings releases; J&J’s quarterly results page lists its releases, presentations, and filings.
Quick Recap
Best Value
- It can be a gift option
- Comes with secure packaging
- Helpful in various ways
Rank #4
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
